Volume 12, Issue 5 pp. 1251-1252
Hepatology Elsewhere
Free Access

Effect of lactulose on the metabolism of short-chain fatty acids

Misael Uribe M.D.

Misael Uribe M.D.

Liver Unit National Institute of Nutrition 1400 Mexico, D.F.

Search for more papers by this author
Octavio Campollo M.D., Ph.D.

Octavio Campollo M.D., Ph.D.

Liver Unit National Institute of Nutrition 1400 Mexico, D.F.

Search for more papers by this author
Christiane Cote M.D.

Christiane Cote M.D.

Liver Unit National Institute of Nutrition 1400 Mexico, D.F.

Search for more papers by this author
First published: November 1990
Citations: 6

Abstract

Short-chain (C2C5) fatty acids account for 60%–70% of the anions in the colon. Acetate (C2) is nontoxic in contrast to C(3)4C5 fatty acids (propionate, butyrate, isobutyrate, valerate, and isovalerate), which induce coma in animals and may be important in the pathogenesis of hepatic coma in humans. An in-vitro fecal incubation system was used to map out short-chain fatty acid production in the presence of lactulose, amino acids, albumin, or blood. Albumin and blood increased production of all C2C5 fatty acids. In contrast, lactulose was converted to acetate only and increased fecal acidity. The degradation of amino acids, albumin, and blood to short-chain fatty acids was completely inhibited by 10–25 mM lactulose. This was caused mainly by the acidifying effect of lactulose. pH-independent inhibition of blood and amino acid degradation to short-chain fatty acids required concentrations of lactulose exceeding 50–100 mM. Thus, the effect of lactulose in the treatment of hepatic coma may be related to its rapid fermentation into organic acids at rates exceeding colonic buffering capacity. This probably reduces formation of toxic fatty acids and ammonia from amino acids, polypeptides, and blood in the colon.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.